Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,405,254
  • Shares Outstanding, K 166,351
  • Annual Sales, $ 2,594 M
  • Annual Income, $ 236,000 K
  • 60-Month Beta 0.46
  • Price/Sales 4.06
  • Price/Cash Flow 20.62
  • Price/Book 4.39
Trade RDY with:

Options Overview

Details
  • Implied Volatility 28.14%
  • Historical Volatility 46.58%
  • IV Percentile 10%
  • IV Rank 15.12%
  • IV High 62.02% on 03/23/21
  • IV Low 22.11% on 08/19/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 987
  • Open Int (30-Day) 852

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.62
  • Growth Rate Est. (year over year) +161,029.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.40 +1.43%
on 08/02/21
75.07 -15.69%
on 07/07/21
-12.00 (-15.94%)
since 07/02/21
3-Month
62.40 +1.43%
on 08/02/21
75.50 -16.17%
on 07/02/21
-7.19 (-10.20%)
since 05/03/21
52-Week
57.54 +9.99%
on 03/18/21
75.50 -16.17%
on 07/02/21
+3.17 (+5.27%)
since 08/03/20

Most Recent Stories

More News
Dr. Reddy's Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve(R) in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the re-launch of over-the-counter...

RDY : 63.29 (+1.07%)
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

RDY : 63.29 (+1.07%)
RGEN : 249.07 (+0.48%)
CORT : 21.58 (+2.66%)
NBRV : 1.2200 (+5.29%)
Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that its Annual Report on Form...

RDY : 63.29 (+1.07%)
Dr. Reddy's Laboratories Announces the Launch of Icosapent Ethyl Capsules, 1 Gram in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Icosapent Ethyl Capsules,...

RDY : 63.29 (+1.07%)
Global Response Aid Reports Midyear Sales Results for COVID Drug

, UAE, /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several...

RDY : 63.29 (+1.07%)
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.

RDY : 63.29 (+1.07%)
ADPT : 35.98 (-2.20%)
ADVM : 2.36 (-0.84%)
MIST : 5.41 (-6.56%)
Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Ertapenem for Injection,...

RDY : 63.29 (+1.07%)
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

TEVA : 9.92 (+0.71%)
RDY : 63.29 (+1.07%)
AMRN : 4.30 (+1.90%)
CDMO : 25.82 (+1.57%)
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Albendazole Tablets,...

RDY : 63.29 (+1.07%)
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller General of India (DCGI) to import the...

RDY : 63.29 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

3rd Resistance Point 64.85
2nd Resistance Point 64.32
1st Resistance Point 63.80
Last Price 63.29
1st Support Level 62.75
2nd Support Level 62.22
3rd Support Level 61.70

See More

52-Week High 75.50
Fibonacci 61.8% 68.64
Fibonacci 50% 66.52
Fibonacci 38.2% 64.40
Last Price 63.29
52-Week Low 57.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar